<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Fertility Preservation & Oncofertility Selective - Welcome Package</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }
        
        body {
            font-family: 'Segoe UI', -apple-system, BlinkMacSystemFont, 'Helvetica Neue', Arial, sans-serif;
            line-height: 1.6;
            color: #2d3748;
            background: #f7fafc;
            padding: 20px;
        }
        
        .container {
            max-width: 1000px;
            margin: 0 auto;
            background: white;
            padding: 40px;
            box-shadow: 0 4px 6px rgba(0,0,0,0.1);
            border-radius: 12px;
        }
        
        header {
            text-align: center;
            margin-bottom: 40px;
            padding-bottom: 30px;
            border-bottom: 3px solid #e2e8f0;
        }
        
        h1 {
            color: #1a202c;
            font-size: 2.5em;
            margin-bottom: 10px;
            font-weight: 700;
        }
        
        .subtitle {
            color: #718096;
            font-size: 1.2em;
            margin-top: 10px;
        }
        
        h2 {
            color: #2c5282;
            font-size: 1.8em;
            margin: 40px 0 20px 0;
            padding-bottom: 10px;
            border-bottom: 2px solid #bee3f8;
        }
        
        h3 {
            color: #2d3748;
            font-size: 1.4em;
            margin: 30px 0 15px 0;
            font-weight: 600;
        }
        
        h4 {
            color: #4a5568;
            font-size: 1.1em;
            margin: 20px 0 10px 0;
            font-weight: 600;
        }
        
        p {
            margin-bottom: 15px;
            text-align: justify;
        }
        
        ul, ol {
            margin: 15px 0 15px 30px;
        }
        
        li {
            margin-bottom: 10px;
        }
        
        .info-box {
            background: #ebf8ff;
            border-left: 4px solid #3182ce;
            padding: 20px;
            margin: 20px 0;
            border-radius: 4px;
        }
        
        .highlight-box {
            background: #fef5e7;
            border-left: 4px solid #f39c12;
            padding: 20px;
            margin: 20px 0;
            border-radius: 4px;
        }
        
        .success-box {
            background: #f0fdf4;
            border-left: 4px solid #10b981;
            padding: 20px;
            margin: 20px 0;
            border-radius: 4px;
        }
        
        .contact-card {
            background: #f7fafc;
            padding: 20px;
            border-radius: 8px;
            margin: 20px 0;
            border: 1px solid #e2e8f0;
        }
        
        .schedule-table {
            width: 100%;
            border-collapse: collapse;
            margin: 20px 0;
        }
        
        .schedule-table th {
            background: #2c5282;
            color: white;
            padding: 12px;
            text-align: left;
            font-weight: 600;
        }
        
        .schedule-table td {
            padding: 12px;
            border-bottom: 1px solid #e2e8f0;
        }
        
        .schedule-table tr:nth-child(even) {
            background: #f7fafc;
        }
        
        .procedure-card {
            background: white;
            border: 2px solid #e2e8f0;
            border-radius: 8px;
            padding: 20px;
            margin: 15px 0;
            transition: box-shadow 0.3s ease;
        }
        
        .procedure-card:hover {
            box-shadow: 0 4px 12px rgba(0,0,0,0.1);
        }
        
        .diagram-container {
            text-align: center;
            margin: 30px 0;
        }
        
        .diagram-container img {
            max-width: 100%;
            height: auto;
            border-radius: 8px;
            box-shadow: 0 4px 6px rgba(0,0,0,0.1);
        }
        
        .toc {
            background: #f7fafc;
            padding: 25px;
            border-radius: 8px;
            margin: 30px 0;
        }
        
        .toc h3 {
            margin-top: 0;
            color: #2c5282;
        }
        
        .toc ul {
            list-style: none;
            margin: 15px 0;
        }
        
        .toc li {
            margin: 8px 0;
        }
        
        .toc a {
            color: #3182ce;
            text-decoration: none;
            font-weight: 500;
        }
        
        .toc a:hover {
            text-decoration: underline;
        }
        
        a {
            color: #3182ce;
            text-decoration: none;
        }
        
        a:hover {
            text-decoration: underline;
        }
        
        .resource-link {
            display: inline-block;
            background: #3182ce;
            color: white;
            padding: 8px 16px;
            border-radius: 4px;
            margin: 5px;
            text-decoration: none;
            transition: background 0.3s ease;
        }
        
        .resource-link:hover {
            background: #2c5282;
            text-decoration: none;
        }
        
        @media print {
            body {
                background: white;
                padding: 0;
            }
            .container {
                box-shadow: none;
                padding: 20px;
            }
        }
    </style>
</head>
<body>
    <div class="container">
        <header>
            <h1>Welcome to the Fertility Preservation & Oncofertility Selective</h1>
            <p class="subtitle">Mount Sinai Hospital | University of Toronto</p>
            <p class="subtitle">Dr. Jennia Michaeli, MD, ObGyn, REI</p>
        </header>

        <!-- Table of Contents -->
        <div class="toc">
            <h3>Contents</h3>
            <ul>
                <li><a href="#welcome">1. Welcome & Overview</a></li>
                <li><a href="#activities">2. Types of Activities & Schedule</a></li>
                <li><a href="#concepts">3. Core Fertility Concepts</a></li>
                <li><a href="#preservation">4. Fertility Preservation & Oncofertility</a></li>
                <li><a href="#resources">5. Resources & Key Papers</a></li>
            </ul>
        </div>

        <!-- Section 1: Welcome & Overview -->
        <section id="welcome">
            <h2>1. Welcome & Overview</h2>
            
            <p>Welcome to one of Ontario's most unique and specialized clinical experiences in reproductive medicine. This selective offers you a rare opportunity to observe and learn about the intersection of reproductive endocrinology, fertility preservation, and oncofertility care.</p>
            
            <div class="diagram-container">
                <img src="specialization_diagram.svg" alt="Clinical Subspecialization Diagram" style="max-width: 600px;">
                <p style="font-style: italic; color: #718096; margin-top: 10px;">Understanding the depth of subspecialization in this field</p>
            </div>

            <h3>Learning Objectives</h3>
            <p>By the end of this selective, you will be able to:</p>
            <ul>
                <li>Understand the comprehensive assessment and management of infertility patients, including observation of advanced reproductive procedures such as oocyte retrieval, embryo transfer, and hysteroscopic procedures</li>
                <li>Recognize the unique considerations in oncofertility care, including fertility preservation options (particularly ovarian tissue cryopreservation), multidisciplinary approaches for pediatric and adult cancer patients, and post-treatment reproductive counseling for cancer survivors</li>
                <li>Gain insight into the clinician-investigator role, balancing clinical excellence with scholarly work including research, manuscript preparation, and academic presentations</li>
            </ul>

            <h3>What Makes This Selective Unique</h3>
            <div class="highlight-box">
                <p><strong>You will witness Ontario's first ovarian tissue cryopreservation (OTC) program</strong> — a groundbreaking service at the forefront of fertility preservation. This program serves patients across the province through a hub-and-spoke model, establishing Mount Sinai as a provincial leader in this emerging field and providing access to cutting-edge reproductive care for patients who would otherwise have limited options.</p>
            </div>

            <h3>Key Contacts</h3>
            <div class="contact-card">
                <h4>Preceptor</h4>
                <p><strong>Dr. Jennia Michaeli, MD, ObGyn, REI</strong><br>
                Reproductive Endocrinology & Infertility Specialist<br>
                Director, Ovarian Tissue Cryopreservation Program & Cancer Survivorship Program, Mount Sinai Fertility<br>
                Co-Director, Fertility Preservation Program at SickKids<br>
                Chair, Fertility Preservation Special Interest Group, Canadian Fertility and Andrology Society<br>
                Assistant Professor, Department of Obstetrics and Gynaecology, University of Toronto<br>
                Email: <a href="mailto:jennia.michaeli@sinaihealth.ca">jennia.michaeli@sinaihealth.ca</a></p>
                
                <h4>Administrative Contact</h4>
                <p>Email: <a href="mailto:Dr.Michaelisoffice@sinaihealth.ca">Dr.Michaelisoffice@sinaihealth.ca</a></p>
            </div>

            <h3>Location</h3>
            <div class="info-box">
                <p><strong>Mount Sinai Hospital - Main Site</strong><br>
                Mount Sinai Fertility<br>
                250 Dundas Street West<br>
                Toronto, Ontario</p>
                
                <p style="margin-top: 15px;"><strong>Satellite Site:</strong><br>
                9600 Bathurst Street, 3rd Floor, Suite 300<br>
                Vaughan, Ontario, L6A 3Z8</p>
                
                <p style="margin-top: 15px;"><strong>Additional Site Visits:</strong><br>
                The Hospital for Sick Children (SickKids) - For pediatric fertility preservation program activities<br>
                Women's College Hospital - For POI (Premature Ovarian Insufficiency) clinics</p>
                
                <p style="margin-top: 15px;"><em>Note: Some days may be conducted virtually or from the Main Site location as appropriate. When Dr. Michaeli is at the Vaughan satellite site, students can join virtually rather than attending in person.</em></p>
            </div>

            <h3>Duration & Expectations</h3>
            <p>This is a two-week selective with <strong>no call required</strong>. You will participate in a mix of clinical activities, procedures, multidisciplinary meetings, and research/academic activities.</p>
            
            <p>You will be observing highly sensitive consultations involving cancer diagnoses, fertility concerns, and life-changing decisions. Professional behavior, empathy, and confidentiality are paramount.</p>
            
            <p>Clinical days can be busy and intense. If at any point you need a break or would like to finish early, please feel free to let me know — this is completely acceptable and encouraged if needed.</p>
        </section>

        <!-- Section 2: Types of Activities & Schedule -->
        <section id="activities">
            <h2>2. Types of Activities & Schedule</h2>
            
            <p>Your two-week experience will include three main types of activities: <strong>Research Days</strong>, <strong>Clinic Days</strong>, and <strong>IVF/Procedure Days</strong>. The specific schedule is below.</p>

            <h3>Your Personalized Schedule</h3>
            <p><strong>Student:</strong> Sophia Lago<br>
            <strong>Selective Dates:</strong> January 5-18, 2026</p>
            
            <table class="schedule-table">
                <tr>
                    <th style="width: 15%;">Date</th>
                    <th style="width: 20%;">Day Type</th>
                    <th style="width: 15%;">Time</th>
                    <th style="width: 50%;">Activities & Special Events</th>
                </tr>
                <tr>
                    <td><strong>Mon, Jan 5</strong></td>
                    <td>Orientation Day</td>
                    <td>9:00 AM - 4:00 PM</td>
                    <td>Welcome meeting, orientation to Mount Sinai Fertility, review of schedule and expectations</td>
                </tr>
                <tr>
                    <td><strong>Tue, Jan 6</strong></td>
                    <td>Clinic Day</td>
                    <td>8:00 AM - 5:00 PM</td>
                    <td>Infertility consultations, follow-up appointments, ultrasound monitoring</td>
                </tr>
                <tr>
                    <td><strong>Wed, Jan 7</strong></td>
                    <td>IVF/Procedure Day</td>
                    <td>7:15 AM - 2:00 PM</td>
                    <td>Oocyte retrievals, embryo transfers, operative hysteroscopy</td>
                </tr>
                <tr>
                    <td><strong>Thu, Jan 8</strong></td>
                    <td>Research Day</td>
                    <td>9:00 AM - 4:00 PM</td>
                    <td>Multidisciplinary meeting (10:00 AM), journal club, manuscript review</td>
                </tr>
                <tr>
                    <td><strong>Fri, Jan 9</strong></td>
                    <td>Clinic Day</td>
                    <td>8:00 AM - 4:00 PM</td>
                    <td>Fertility preservation consultations, Cancer Survivorship Clinic</td>
                </tr>
                <tr>
                    <td><strong>Mon, Jan 12</strong></td>
                    <td>IVF/Procedure Day</td>
                    <td>7:15 AM - 2:00 PM</td>
                    <td>Oocyte retrievals, sonohysterogram, office hysteroscopy</td>
                </tr>
                <tr>
                    <td><strong>Tue, Jan 13</strong></td>
                    <td>SickKids Visit</td>
                    <td>9:00 AM - 3:00 PM</td>
                    <td>Pediatric fertility preservation consultations at The Hospital for Sick Children</td>
                </tr>
                <tr>
                    <td><strong>Wed, Jan 14</strong></td>
                    <td>Clinic Day</td>
                    <td>8:00 AM - 5:00 PM</td>
                    <td>General infertility clinic, treatment planning discussions</td>
                </tr>
                <tr>
                    <td><strong>Thu, Jan 15</strong></td>
                    <td>Research Day</td>
                    <td>9:00 AM - 4:00 PM</td>
                    <td>Research presentation preparation, data analysis, educational rounds</td>
                </tr>
                <tr>
                    <td><strong>Fri, Jan 16</strong></td>
                    <td>IVF/Procedure Day</td>
                    <td>7:15 AM - 2:00 PM</td>
                    <td>Oocyte retrievals, embryo transfers, OTC consultation</td>
                </tr>
                <tr>
                    <td><strong>Mon, Jan 18</strong></td>
                    <td>Wrap-up Day</td>
                    <td>9:00 AM - 12:00 PM</td>
                    <td>Case review, feedback session, Q&A</td>
                </tr>
            </table>

            <p style="margin-top: 20px; font-style: italic; color: #718096;">*This schedule is a template and will be customized based on clinical volume and patient scheduling. You will receive your finalized schedule before your rotation begins.</p>

            <h3>A. Research Days</h3>
            <p>Research days provide insight into the <strong>clinician-investigator role</strong> — balancing clinical excellence with advancing the field through research, clinical trials, guideline development, and publishing outcomes that shape practice standards. These days demonstrate how clinical expertise informs research questions and how evidence-based practice evolves.</p>
            
            <h4>Activities Include:</h4>
            <ul>
                <li><strong>Multidisciplinary Team Meetings & Educational Rounds:</strong> Collaborative discussions with reproductive endocrinologists, oncologists, pediatric specialists, and allied health professionals reviewing complex cases and teaching fertility preservation topics</li>
                <li><strong>Research & Scholarly Work:</strong> Journal club discussions, critical appraisal of current literature, manuscript review and writing, data analysis, and preparation of academic presentations for conferences</li>
            </ul>

            <h3>B. Clinic Days</h3>
            <p>Clinic days involve multiple clinical encounters and can be conducted either in person or virtually. All clinical data is stored in the <strong>eIVF EMR system</strong>, which students can access to review patient information and learn their stories in advance of appointments.</p>
            
            <div class="info-box">
                <p><strong>Preparation:</strong> The day before clinic, you will receive an email with links to all clinical encounters via OTN (Ontario Telemedicine Network). Review patient charts in eIVF to familiarize yourself with each case before the appointments.</p>
            </div>

            <h4>Types of Clinical Encounters:</h4>
            <ul>
                <li><strong>New Patient Consultations:</strong> Comprehensive infertility assessments for patients beginning their fertility journey</li>
                <li><strong>Follow-up Visits:</strong> Ongoing infertility management, treatment monitoring, and cycle planning</li>
                <li><strong>Fertility Preservation Consultations:</strong> Counseling patients facing gonadotoxic cancer treatments or other medical conditions</li>
                <li><strong>Cancer Survivorship Fertility Clinic:</strong> Dedicated clinic sessions (once monthly on Fridays) for post-treatment reproductive counseling and assessment of fertility options for cancer survivors</li>
            </ul>

            <h3>C. IVF/Procedure Days</h3>
            <p>These are hands-on clinical days where you'll observe the full spectrum of reproductive procedures and patient care. Some days start at <strong>7:15 AM</strong>, others at <strong>8:00 AM</strong> — check eIVF the night before to confirm your start time. Please arrive on time as procedures begin promptly. Scrubs can be obtained on site.</p>

            <h4>Procedures You Will Observe:</h4>
            
            <div class="procedure-card">
                <h4>Operative Hysteroscopy</h4>
                <p><strong>What it is:</strong> A minimally invasive surgical procedure to diagnose and treat intrauterine pathology using a hysteroscope (a thin, lighted telescope) inserted through the cervix.</p>
                <p><strong>Common indications:</strong> Removal of uterine polyps, submucosal fibroids, uterine septum, or intrauterine adhesions that may impair fertility.</p>
                <p><strong>Clinical significance:</strong> Optimizing the uterine cavity is crucial before embryo transfer or attempting conception.</p>
            </div>

            <div class="procedure-card">
                <h4>Oocyte Retrieval (Egg Retrieval)</h4>
                <p><strong>What it is:</strong> An ultrasound-guided transvaginal procedure to aspirate mature oocytes from ovarian follicles after controlled ovarian stimulation.</p>
                <p><strong>Context:</strong> This is performed for both infertility treatment (IVF) and fertility preservation (oocyte cryopreservation).</p>
                <p><strong>What you'll observe:</strong> Patient preparation, conscious sedation, ultrasound guidance, aspiration technique, and immediate embryology lab communication.</p>
            </div>

            <div class="procedure-card">
                <h4>Embryo Transfer</h4>
                <p><strong>What it is:</strong> The final step of IVF where a selected embryo is transferred into the uterus using a thin catheter under ultrasound guidance.</p>
                <p><strong>What you'll observe:</strong> The delicate technique required, ultrasound visualization, catheter selection, and the "gentle touch" approach that maximizes success.</p>
            </div>

            <div class="procedure-card">
                <h4>Sonohysterogram (Saline Infusion Sonography)</h4>
                <p><strong>What it is:</strong> An ultrasound procedure where sterile saline is infused into the uterine cavity to better visualize the endometrium and detect pathology.</p>
                <p><strong>Indications:</strong> Evaluation of abnormal uterine bleeding, suspected polyps, fibroids, uterine anomalies, and tubal patency testing.</p>
            </div>

            <div class="procedure-card">
                <h4>Office Hysteroscopy</h4>
                <p><strong>What it is:</strong> Diagnostic visualization of the uterine cavity using a narrow hysteroscope in the office setting without anesthesia.</p>
                <p><strong>When performed:</strong> Initial assessment of uterine cavity, evaluation of abnormal bleeding, confirmation of suspected intrauterine pathology.</p>
            </div>

            <h4>MD2 Role - Treatment Cycle Management</h4>
            <p>You will also observe the <strong>MD2 role</strong>, where Dr. Michaeli reviews all blood work and ultrasounds for patients in active fertility treatment. This involves making real-time clinical decisions regarding all types of treatment cycles including IVF, embryo transfers, IUI (intrauterine insemination), TIC (timed intercourse cycles), and random day assessments. A link for blood round review will be provided to you.</p>
        </section>

        <!-- Section 3: Core Fertility Concepts -->
        <section id="concepts">
            <h2>3. Core Fertility Concepts</h2>
            
            <p>Before diving into the specialized world of fertility preservation and oncofertility, it's helpful to understand some foundational concepts in reproductive endocrinology and infertility.</p>

            <h3>Basic Reproductive Physiology</h3>
            
            <h4>The Menstrual Cycle</h4>
            <p>Understanding the menstrual cycle is fundamental to all fertility care:</p>
            <ul>
                <li><strong>Follicular Phase:</strong> FSH stimulates follicle growth; naturally only one dominant follicle emerges</li>
                <li><strong>Ovulation:</strong> LH surge triggers the release of a mature oocyte (around day 14)</li>
                <li><strong>Luteal Phase:</strong> Corpus luteum produces progesterone to support a potential pregnancy</li>
            </ul>

            <h4>Ovarian Reserve</h4>
            <p><strong>Definition:</strong> The quantity of oocytes remaining in the ovaries. This is <strong>NOT</strong> a predictor of fertility potential! But it is an important marker for how many oocytes can be obtained in fertility treatment, helpful in determining the dose of medications and treatment protocols.</p>
            
            <p><strong>Assessment methods:</strong></p>
            <ul>
                <li><strong>Antral Follicle Count (AFC):</strong> Ultrasound count of small follicles (2-10mm) on days 2-5 of cycle, in both ovaries</li>
                <li><strong>Anti-Müllerian Hormone (AMH):</strong> Blood test that correlates with ovarian reserve; can be done any time in cycle. Dr. Michaeli's calculator: <a href="https://amh.fertilitypreservation.ca/" target="_blank">https://amh.fertilitypreservation.ca/</a></li>
                <li><strong>FSH & Estradiol:</strong> Day 2-3 levels; elevated FSH suggests diminished reserve, not as commonly used as a marker</li>
            </ul>

            <div class="info-box">
                <h4>Why Ovarian Reserve Matters in Oncofertility</h4>
                <p>Cancer treatments (chemotherapy, radiation) can significantly damage ovarian reserve. The extent of damage depends on the patient's age, baseline reserve, and the degree of gonadotoxicity of the treatment regimen. This is why fertility preservation before treatment is so critical, and follow-up in survivorship can help guide family planning and possible preservation options in the future.</p>
            </div>

            <h3>Controlled Ovarian Stimulation</h3>
            <p>This is the process of using medications to stimulate multiple follicles to grow simultaneously — essential for both IVF and fertility preservation.</p>

            <h4>Key Processes and Medications Involved:</h4>
            <p>Ovarian stimulation involves three main phases using medications for stimulation and suppression of premature ovulation:</p>
            
            <ol>
                <li><strong>Stimulation Phase:</strong> Using gonadotropins to promote multiple follicle development</li>
                <li><strong>Suppression Phase:</strong> Preventing premature ovulation with GnRH antagonists or agonists</li>
                <li><strong>Trigger Phase:</strong> Inducing final oocyte maturation before retrieval</li>
            </ol>

            <p><strong>Key Medications:</strong></p>
            <ul>
                <li><strong>Gonadotropins (FSH/LH):</strong> Injectable hormones that stimulate follicle development</li>
                <li><strong>GnRH Antagonists:</strong> Prevent premature ovulation (e.g., Cetrotide, Ganirelix)</li>
                <li><strong>GnRH Agonists:</strong> Can be used for "trigger" (final oocyte maturation) or for pituitary suppression</li>
                <li><strong>hCG Trigger:</strong> Mimics the natural LH surge to trigger final egg maturation 36 hours before retrieval</li>
            </ul>

            <h4>Random Start Protocols</h4>
            <p><strong>Important for oncofertility:</strong> Traditional IVF cycles start on day 2-3 of menses. However, cancer patients can't always wait. Random start (or luteal phase start) protocols allow stimulation to begin at any point in the cycle — critical when treatment must begin urgently.</p>

            <h3>Key Terminology</h3>
            <ul>
                <li><strong>AFC (Antral Follicle Count):</strong> Number of small follicles visible on ultrasound; marker of ovarian reserve</li>
                <li><strong>Agonist:</strong> Medication that activates a receptor (e.g., GnRH agonist)</li>
                <li><strong>AMH (Anti-Müllerian Hormone):</strong> Blood test measuring ovarian reserve</li>
                <li><strong>Antagonist:</strong> Medication that blocks a receptor (e.g., GnRH antagonist)</li>
                <li><strong>Atresia:</strong> Natural degeneration of follicles</li>
                <li><strong>Corpus Luteum:</strong> Structure formed after ovulation that produces progesterone</li>
                <li><strong>Cryopreservation:</strong> Freezing for storage</li>
                <li><strong>Follicle:</strong> Fluid-filled sac in the ovary containing an oocyte</li>
                <li><strong>FSH (Follicle Stimulating Hormone):</strong> Hormone that stimulates follicle growth</li>
                <li><strong>GnRH (Gonadotropin-Releasing Hormone):</strong> Brain hormone that controls FSH/LH release</li>
                <li><strong>Gonadotoxic:</strong> Toxic to the gonads (ovaries/testes); refers to treatments that can damage fertility</li>
                <li><strong>hCG (Human Chorionic Gonadotropin):</strong> Hormone used to trigger final egg maturation</li>
                <li><strong>LH (Luteinizing Hormone):</strong> Hormone that triggers ovulation</li>
                <li><strong>Oocyte:</strong> Egg cell</li>
                <li><strong>OTC (Ovarian Tissue Cryopreservation):</strong> Freezing ovarian cortex for future transplantation</li>
                <li><strong>Primordial Follicles:</strong> Microscopic "dormant" follicles representing the true ovarian reserve; cannot be directly measured, but correlates with functional ovarian reserve</li>
                <li><strong>Vitrification:</strong> Ultra-rapid freezing technique used for egg and embryo cryopreservation</li>
                <li><strong>Advanced Reproductive Age:</strong> Typically refers to women aged 35 and older, when fertility naturally declines and pregnancy risks increase</li>
                <li><strong>COS-IUI (Controlled Ovarian Stimulation with Intrauterine Insemination):</strong> Fertility treatment combining ovarian stimulation medications with timed placement of sperm directly into the uterus</li>
                <li><strong>Diminished Ovarian Reserve (DOR):</strong> Reduced quantity and/or quality of oocytes, indicated by low AMH, low AFC, or elevated FSH levels</li>
                <li><strong>IVF (In Vitro Fertilization):</strong> Fertility treatment where eggs are retrieved, fertilized with sperm in a laboratory, and resulting embryos are transferred to the uterus</li>
                <li><strong>Male Factor Infertility:</strong> Infertility caused by issues with sperm production, function, or delivery; accounts for approximately 40-50% of infertility cases</li>
                <li><strong>Ovulation Induction:</strong> Use of medications (letrozole, clomiphene/Clomid, or gonadotropins) to stimulate ovulation in women who don't ovulate regularly</li>
                <li><strong>POI (Premature Ovarian Insufficiency):</strong> Loss of ovarian function before age 40, also known as premature menopause; can result from cancer treatment, autoimmune conditions, or genetic factors</li>
                <li><strong>Third Party Reproduction:</strong> Use of donated eggs, sperm, embryos, or gestational carriers (surrogates) to achieve pregnancy when using one's own gametes is not possible</li>
                <li><strong>Unexplained Infertility:</strong> Infertility diagnosis when standard testing fails to identify a specific cause; accounts for approximately 15-30% of infertility cases</li>
            </ul>
        </section>

        <!-- Section 4: Fertility Preservation & Oncofertility -->
        <section id="preservation">
            <h2>4. Fertility Preservation & Oncofertility</h2>
            
            <p><strong>Oncofertility</strong> is an emerging field that bridges oncology and reproductive medicine, focusing on preserving and restoring fertility in cancer patients and survivors.</p>

            <h3>Why Fertility Preservation Matters</h3>
            <div class="info-box">
                <p>Approximately 3,000 patients below age 39 are diagnosed with cancer in Ontario annually. Many are in their reproductive years when fertility is a significant life priority. Cancer treatments can cause:</p>
                <ul>
                    <li><strong>In females:</strong> Permanent ovarian failure (premature menopause), diminished ovarian reserve, DNA damage to remaining oocytes, uterine damage from radiation</li>
                    <li><strong>In males:</strong> Reduced sperm production, azoospermia (complete absence of sperm), DNA damage to sperm</li>
                    <li><strong>Psychosocial impact:</strong> Severe fertility-related distress and concerns about future family building, which can significantly affect quality of life and cancer survivorship</li>
                </ul>
                <p><strong>The window for fertility preservation is narrow</strong> — ideally, it must occur before gonadotoxic treatment begins. However, assessment of fertility function in survivorship can offer additional opportunities for fertility preservation and help plan family building strategies to avoid missed opportunities and regret.</p>
            </div>

            <h3>Patient Populations</h3>
            
            <h4>Cancer Patients</h4>
            <ul>
                <li><strong>Newly diagnosed:</strong> Fertility preservation before chemotherapy/radiation</li>
                <li><strong>Survivors:</strong> Assessment and reproductive counseling after treatment</li>
                <li><strong>Pediatric patients:</strong> Special considerations for pre-pubertal children and adolescents</li>
            </ul>

            <h4>Other Indications</h4>
            <ul>
                <li><strong>Benign conditions requiring gonadotoxic treatment:</strong> Hemoglobinopathies (Thalassemia, Sickle Cell Disease), severe autoimmune disease, bone marrow transplant for non-malignant conditions</li>
                <li><strong>Gender-affirming care:</strong> Fertility preservation before gender-affirming hormone therapy or surgery</li>
                <li><strong>Planned egg freezing:</strong> Elective oocyte cryopreservation</li>
            </ul>

            <h3>Fertility Preservation Options</h3>

            <h4>Established Options (Standard of Care)</h4>
            
            <div class="procedure-card">
                <h4>Oocyte Cryopreservation (Egg Freezing)</h4>
                <p><strong>Best for:</strong> Post-pubertal females with adequate time for ovarian stimulation (typically 2 weeks)</p>
                <p><strong>Process:</strong> Controlled ovarian stimulation → oocyte retrieval → vitrification</p>
                <p><strong>Advantages:</strong> No partner/sperm needed; eggs belong to patient alone</p>
                <p><strong>Success rates:</strong> Age-dependent; generally 30-60% live birth rate per ~15-20 mature eggs</p>
                <p><strong>Considerations:</strong> Requires 10-14 days; hormone-sensitive cancers may need special protocols</p>
            </div>

            <div class="procedure-card">
                <h4>Embryo Cryopreservation</h4>
                <p><strong>Best for:</strong> Patients with a partner or using donor sperm</p>
                <p><strong>Process:</strong> Same as oocyte cryopreservation, but eggs are fertilized before freezing</p>
                <p><strong>Advantages:</strong> Embryo is closer to the target of live birth, providing a more realistic estimation of success with less uncertainty about outcomes. Success rates of embryos and eggs are now considered equivalent.</p>
                <p><strong>Considerations:</strong> Requires partner/donor decision; legal/ethical considerations</p>
            </div>

            <div class="procedure-card">
                <h4>Ovarian Tissue Cryopreservation (OTC)</h4>
                
                <p><strong>Best for:</strong></p>
                <ul>
                    <li>Pre-pubertal girls who cannot undergo ovarian stimulation</li>
                    <li>Patients who cannot delay cancer treatment for 2 weeks</li>
                    <li>Very aggressive chemotherapy regimens likely to cause complete ovarian failure</li>
                </ul>
                
                <p><strong>The Procedure:</strong></p>
                <ul>
                    <li>Laparoscopic removal of part or whole ovary</li>
                    <li>Ovarian cortex (outer layer containing primordial follicles) is dissected into strips</li>
                    <li>Tissue is cryopreserved using slow-freeze protocols</li>
                    <li>Can be done any time in menstrual cycle</li>
                    <li>Usually takes 1-2 hours; patient goes home same day</li>
                    <li><strong>Remote tissue harvesting:</strong> Tissue can be harvested at remote sites and transported to Mount Sinai Fertility for processing — this is the only program in Canada offering this service, bringing access to care across the province</li>
                </ul>
                
                <p><strong>Future use:</strong></p>
                <ul>
                    <li><strong>Orthotopic transplantation:</strong> Tissue grafted back into pelvic cavity near remaining ovary or at ovarian site</li>
                    <li><strong>Heterotopic transplantation:</strong> Grafted to accessible site like forearm (research)</li>
                </ul>
                
                <p><strong>Current status:</strong> Over 200 live births worldwide from OTC. No longer considered experimental by ASRM (as of 2019). Success rates are similar to embryo and egg freezing, but these are international reports, and there is no Canadian baby from ovarian tissue re-transplantation since it has not been attempted yet.</p>
            </div>

            <div class="procedure-card">
                <h4>Sperm Cryopreservation (Sperm Freezing)</h4>
                <p><strong>Best for:</strong> Post-pubertal males before gonadotoxic treatment</p>
                <p><strong>Process:</strong> Semen sample collected via masturbation, processed, and cryopreserved</p>
                <p><strong>Advantages:</strong> Simple, non-invasive procedure; can be done quickly before treatment</p>
                <p><strong>Considerations:</strong> May be challenging for adolescents; multiple samples recommended when time permits</p>
            </div>

            <div class="procedure-card">
                <h4>Testicular Sperm Extraction</h4>
                <p><strong>Best for:</strong> Males unable to produce ejaculated sperm (azoospermia, neurological conditions)</p>
                
                <p><strong>Methods:</strong></p>
                <ul>
                    <li><strong>Micro-TESE (Microdissection Testicular Sperm Extraction):</strong> Surgical procedure using microscope to identify seminiferous tubules most likely to contain sperm</li>
                    <li><strong>Electroejaculation:</strong> Electrical stimulation to induce ejaculation in patients with spinal cord injuries or neurological conditions preventing natural ejaculation</li>
                </ul>
            </div>

            <h4>Emerging/Experimental Options</h4>
            
            <div class="procedure-card">
                <h4>In Vitro Maturation (IVM)</h4>
                <p><strong>What it is:</strong> Collection of immature oocytes from unstimulated or minimally stimulated ovaries, followed by maturation in the laboratory</p>
                <p><strong>Potential advantages:</strong> Avoids ovarian stimulation, can be performed urgently</p>
                <p><strong>Status:</strong> Lower success rates than conventional IVF; currently only offered experimentally in the context of OTC for ovarian tissue-derived oocytes</p>
            </div>

            <div class="procedure-card">
                <h4>Uterine Transposition and Transplantation</h4>
                <p><strong>Uterine transposition:</strong> Surgical repositioning of the uterus outside the radiation field to minimize damage during pelvic radiation</p>
                <p><strong>Uterine transplantation:</strong> Transplanting a donor uterus to enable pregnancy in women born without a uterus or who lost uterine function</p>
                <p><strong>Status:</strong> Currently not performed in Canada; several successful pregnancies reported worldwide from uterine transplantation</p>
            </div>

            <h3>Gonadotoxicity Risk Stratification</h3>
            <p>Different cancer treatments carry different risks to fertility:</p>
            
            <table class="schedule-table">
                <tr>
                    <th>Risk Level</th>
                    <th>Examples</th>
                    <th>Estimated Risk</th>
                </tr>
                <tr>
                    <td><strong>High Risk</strong></td>
                    <td>Cyclophosphamide (high dose), whole abdominal/pelvic radiation, total body irradiation, bone marrow transplant conditioning</td>
                    <td>&gt;80% risk of premature ovarian insufficiency</td>
                </tr>
                <tr>
                    <td><strong>Intermediate Risk</strong></td>
                    <td>Doxorubicin-based regimens, cyclophosphamide (moderate dose), carboplatin</td>
                    <td>Variable, age-dependent</td>
                </tr>
                <tr>
                    <td><strong>Low/Unknown Risk</strong></td>
                    <td>Vincristine, methotrexate, 5-FU, targeted therapies</td>
                    <td>&lt;20% risk</td>
                </tr>
            </table>

            <div class="info-box">
                <p><strong>Age is the most important modifier:</strong> A 38-year-old receiving "low-risk" chemotherapy may still experience ovarian failure, while a 22-year-old receiving "high-risk" treatment may retain some ovarian function.</p>
            </div>

            <h3>The Cancer Survivorship Fertility Clinic</h3>
            <p>This specialized clinic serves patients who have completed cancer treatment and are now considering their reproductive options.</p>
            
            <h4>What you'll observe:</h4>
            <ul>
                <li><strong>Ovarian reserve assessment:</strong> AFC, AMH testing to determine remaining ovarian reserve</li>
                <li><strong>Counseling on conception timing:</strong> How long to wait after treatment; considerations for recurrence risk, reproductive potential assessment</li>
                <li><strong>Discussion of pregnancy safety:</strong> Cancer-specific considerations (e.g., breast cancer and pregnancy), gonadotoxic exposure and children's health, genetic predisposition to cancer (BRCA and other genetic conditions)</li>
                <li><strong>Use of preserved tissue/eggs/embryos:</strong> Discussing next steps for those who preserved fertility</li>
                <li><strong>Egg/sperm donation counseling:</strong> For those with ovarian/testicular insufficiency</li>
                <li><strong>Third-party reproduction options:</strong> Gestational carrier for those who cannot safely carry a pregnancy</li>
            </ul>

            <h3>Pediatric Fertility Preservation</h3>
            <p>Fertility preservation in children presents unique medical, ethical, and psychological challenges. The Fertility Preservation Program at SickKids provides this unique care in partnership with Mount Sinai Fertility.</p>

            <h4>Special Considerations:</h4>
            <ul>
                <li><strong>Consent/assent:</strong> Balancing parental consent with child assent when appropriate</li>
                <li><strong>Pre-pubertal patients:</strong> Limited options (OTC is primary option)</li>
                <li><strong>Post-pubertal patients:</strong> Similar options to adults, but additional psychological support needed</li>
                <li><strong>Timing pressures:</strong> Must balance oncologic urgency with fertility preservation</li>
                <li><strong>Uncertainty:</strong> Unknown future fertility desires; talking about sexuality/reproduction with children/adolescents</li>
                <li><strong>Multidisciplinary approach:</strong> Pediatric fertility preservation requires coordination between pediatric oncologists, reproductive endocrinologists, pediatric gynecologists, social workers and psychologists, bioethicists, and the child's family</li>
            </ul>

            <h3>Ethical Considerations</h3>
            <p>Oncofertility raises profound ethical questions that I invite you to explore:</p>
            <ul>
                <li>Balancing life-saving cancer treatment urgency with fertility preservation</li>
                <li>Informed consent when patients are in crisis</li>
                <li>Disposition of stored tissue/eggs/embryos if the patient doesn't survive cancer</li>
                <li>Cost and access to care (fertility preservation often incurs unexpected additional expenses that are not covered by insurance)</li>
                <li>Posthumous reproduction from stored gametes</li>
                <li>Use of experimental procedures in vulnerable populations</li>
            </ul>
        </section>

        <!-- Section 5: Resources -->
        <section id="resources">
            <h2>5. Resources & Key Papers</h2>
            
            <p>The following resources are <strong>recommended, but not mandatory</strong> reading to help you prepare for the selective and deepen your understanding. You don't need to read all of these — explore what interests you. I am happy to advise additional resources to accommodate questions that arise during clinical encounters.</p>

            <h3>Recommended Pre-Reading</h3>
            <div class="info-box">
                <h4>Before Your First Day:</h4>
                <ul>
                    <li>Review basic reproductive endocrinology and menstrual cycle physiology</li>
                    <li>Familiarize yourself with the procedures listed in Section 2</li>
                    <li>Read about the basics of IVF and fertility preservation</li>
                </ul>
            </div>

            <h3>Recommended Papers & Guidelines</h3>
            <ul>
                <li><a href="https://academic.oup.com/humupd/advance-article-abstract/doi/10.1093/humupd/dmaf026/8315986?redirectedFrom=fulltext&login=false" target="_blank">Ovarian tissue cryopreservation and transplantation - Human Update (2024)</a></li>
                <li><a href="https://pubmed.ncbi.nlm.nih.gov/41206517/" target="_blank">Recent advances in fertility preservation - PubMed</a></li>
                <li><a href="https://cfas.ca/_Library/2020positionstatements/CFAS-Position-Statement-Ovarian-Cryo-Formatted.pdf" target="_blank">CFAS Position Statement on Ovarian Tissue Cryopreservation</a></li>
                <li><a href="https://www.sciencedirect.com/science/article/pii/S1472648323008660" target="_blank">Fertility preservation in cancer patients - Best Practice & Research Clinical Obstetrics & Gynaecology</a></li>
                <li><a href="https://www.asrm.org/practice-guidance/practice-committee-documents/fertility-preservation-in-patients-undergoing-gonadotoxic-therapy-or-gonadectomy-a-committee-opinion-2019/" target="_blank">ASRM Committee Opinion: Fertility Preservation in Patients Undergoing Gonadotoxic Therapy (2019)</a></li>
                <li><a href="https://ascopubs.org/doi/10.1200/JCO-24-02782" target="_blank">ASCO Guidelines on Fertility Preservation for Cancer Patients</a></li>
            </ul>

            <h3>Recommended Textbooks</h3>
            <ol>
                <li><strong>Speroff's Clinical Gynecologic Endocrinology and Infertility</strong> - 10th edition</li>
                <li><strong>Yen & Jaffe's Reproductive Endocrinology</strong> - 9th edition</li>
                <li><strong>Principles and Practice of Ovarian Tissue Cryopreservation and Transplantation</strong> - 1st Edition<br>
                <em>The electronic version (PDF) is available on the X-drive</em></li>
                <li><strong>Textbook of Assisted Reproductive Techniques</strong> - 2 volumes, 6th edition<br>
                <em>Available through the UofT library</em></li>
            </ol>

            <h3>Educational Websites & Webinars</h3>
            <ul>
                <li><strong>Oncofertility Consortium (MSU):</strong> <a href="https://oncofertility.msu.edu/" target="_blank">oncofertility.msu.edu</a><br>
                Oncofertility-related information, multiple webinars, and written information (go to the Education tab on the menu). This organization also has an amazing YouTube channel with lots of educational materials.</li>
                <li><strong>IVF Worldwide:</strong> <a href="https://ivf-worldwide.com/" target="_blank">ivf-worldwide.com</a><br>
                International website with multiple webinars and written summaries on multiple topics in ART (go to the Research & Education and IVF Webinar Series tabs on the menu)</li>
                <li><strong>RBMO Journal YouTube Channel:</strong> <a href="https://www.youtube.com/playlist?list=PLYJorode6XaYgA_pJPugdHvRTMf3ijOOO" target="_blank">RBMO Webinar Series</a><br>
                If you like webinars, check out this excellent collection of educational content</li>
            </ul>

            <h3>Key Organizations & Guidelines</h3>
            <ul>
                <li><strong>American Society for Reproductive Medicine (ASRM):</strong> <a href="https://www.asrm.org" target="_blank">www.asrm.org</a></li>
                <li><strong>American Society of Clinical Oncology (ASCO):</strong> <a href="https://www.asco.org" target="_blank">www.asco.org</a></li>
                <li><strong>Canadian Fertility and Andrology Society (CFAS):</strong> <a href="https://cfas.ca" target="_blank">cfas.ca</a></li>
                <li><strong>Oncofertility Consortium:</strong> <a href="https://oncofertility.northwestern.edu" target="_blank">oncofertility.northwestern.edu</a></li>
            </ul>
        </section>

        <footer style="margin-top: 60px; padding-top: 30px; border-top: 2px solid #e2e8f0; text-align: center; color: #718096;">
            <p>Mount Sinai Hospital | University of 